Publications by authors named "L Mulroy"
Purpose: Long-term randomized data assessing the effect of ablative therapies in patients with oligometastases are lacking. The Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastases (SABR-COMET) randomized phase 2 trial was originally designed with 5 years of follow-up, but the trial was amended in 2016 to extend follow-up to 10 years. Herein we report oncologic outcomes beyond 5 years.
View Article and Find Full Text PDFImportance: Palliative thoracic radiotherapy (RT) can alleviate local symptoms associated with advanced non-small cell lung cancer (NSCLC), but esophagitis is a common treatment-related adverse event. Whether esophageal-sparing intensity-modulated RT (ES-IMRT) achieves a clinically relevant reduction in esophageal symptoms remains unclear.
Objective: To examine whether ES-IMRT achieves a clinically relevant reduction in esophageal symptoms compared with standard RT.
Purpose: The phase 2 randomized study SABR-COMET demonstrated that in patients with controlled primary tumors and 1 to 5 oligometastatic lesions, SABR was associated with improved progression-free survival (PFS) compared with standard of care (SoC), but with higher costs and treatment-related toxicities. The aim of this study was to assess the cost-effectiveness of SABR versus SoC in this setting.
Methods And Materials: A Markov model was constructed to perform a cost-utility analysis from the Canadian health care system perspective.
Cerebellopontine angle (CPA) tumours account for 6-10% of intracranial tumours. The most common CPA tumours are vestibular schwannomas (VS), also known as acoustic neuromas, benign tumours of the vestibulocochlear nerve. Less common but symptomatic skull base lesions are glomus jugulare tumours (GJT), of which approximately 40% are identified as CPA tumours.
View Article and Find Full Text PDFArticle Synopsis
- The study explores the oligometastatic paradigm, proposing that patients with a limited number of metastases may benefit from aggressive treatment like stereotactic ablative radiotherapy (SABR) to achieve long-term control or possible cure.
- Researchers enrolled 99 patients with a controlled primary cancer and 1-5 metastatic lesions, randomly assigning them to receive either standard-of-care treatment alone or standard care plus SABR, with primary and secondary outcomes focusing on overall survival, progression-free survival, and quality of life.
- Results showed significantly better 5-year overall survival (42.3% vs. 17.7%) and progression-free survival (17.3% vs. not reached) in the SABR plus SOC group